BioSpecifics Technologies Corp Company Profile (NASDAQ:BSTC)

About BioSpecifics Technologies Corp (NASDAQ:BSTC)

BioSpecifics Technologies Corp logoBioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BSTC
  • CUSIP: 09093110
  • Web: www.biospecifics.com
Capitalization:
  • Market Cap: $330.7 million
  • Outstanding Shares: 7,164,000
Average Prices:
  • 50 Day Moving Avg: $46.68
  • 200 Day Moving Avg: $50.85
  • 52 Week Range: $38.89 - $58.79
P/E:
  • Trailing P/E Ratio: 28.32
  • Foreward P/E Ratio: 27.31
  • P/E Growth: 1.33
Sales & Book Value:
  • Annual Revenue: $27.73 million
  • Price / Sales: 11.93
  • Book Value: $8.66 per share
  • Price / Book: 5.33
Profitability:
  • EBIDTA: $18.65 million
  • Net Margins: 43.06%
  • Return on Equity: 20.65%
  • Return on Assets: 17.98%
Debt:
  • Current Ratio: 23.09%
  • Quick Ratio: 23.09%
Misc:
  • Average Volume: 24,859 shs.
  • Beta: 1.76
  • Short Ratio: 4.98
 

Frequently Asked Questions for BioSpecifics Technologies Corp (NASDAQ:BSTC)

What is BioSpecifics Technologies Corp's stock symbol?

BioSpecifics Technologies Corp trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies Corp's earnings last quarter?

BioSpecifics Technologies Corp (NASDAQ:BSTC) released its quarterly earnings results on Wednesday, March, 15th. The company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.02. The firm earned $6.62 million during the quarter, compared to analysts' expectations of $6.76 million. BioSpecifics Technologies Corp had a net margin of 43.06% and a return on equity of 20.65%. View BioSpecifics Technologies Corp's Earnings History.

When will BioSpecifics Technologies Corp make its next earnings announcement?

BioSpecifics Technologies Corp is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for BioSpecifics Technologies Corp.

Where is BioSpecifics Technologies Corp's stock going? Where will BioSpecifics Technologies Corp's stock price be in 2017?

1 brokers have issued 12-month target prices for BioSpecifics Technologies Corp's shares. Their predictions range from $72.00 to $72.00. On average, they expect BioSpecifics Technologies Corp's share price to reach $72.00 in the next year. View Analyst Ratings for BioSpecifics Technologies Corp.

What are analysts saying about BioSpecifics Technologies Corp stock?

Here are some recent quotes from research analysts about BioSpecifics Technologies Corp stock:

  • 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (8/11/2017)
  • 2. HC Wainwright analysts commented, "We have adjusted our revenue projection for BSTC accordingly, and our current 2017 revenue projection is $28.0M vs. the prior $29.6M, suggesting 7% YoY growth, while our 2018 revenue estimate is now $29.4M vs. the prior $32M." (8/10/2017)

Who are some of BioSpecifics Technologies Corp's key competitors?

Who are BioSpecifics Technologies Corp's key executives?

BioSpecifics Technologies Corp's management team includes the folowing people:

  • Thomas L. Wegman, President, Principal Executive Officer, Principal Financial Officer, Director
  • Mark N. Wegman Ph.D., Director
  • Toby Wegman, Director
  • Jennifer M. Chao, Independent Director
  • Paul A. Gitman M.D., Independent Director
  • George M. Gould J.D., Independent Director

Who owns BioSpecifics Technologies Corp stock?

BioSpecifics Technologies Corp's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.56%), Dimensional Fund Advisors LP (3.70%), Vanguard Group Inc. (2.80%), Eagle Asset Management Inc. (2.54%), Acadian Asset Management LLC (2.30%) and Rice Hall James & Associates LLC (2.25%). Company insiders that own BioSpecifics Technologies Corp stock include Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies Corp.

Who sold BioSpecifics Technologies Corp stock? Who is selling BioSpecifics Technologies Corp stock?

BioSpecifics Technologies Corp's stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Globeflex Capital L P, First Quadrant L P CA, GSA Capital Partners LLP, Wells Fargo & Company MN, Acadian Asset Management LLC, Alliancebernstein L.P. and Northpointe Capital LLC. Company insiders that have sold BioSpecifics Technologies Corp stock in the last year include Thomas Wegman and Toby Wegman. View Insider Buying and Selling for BioSpecifics Technologies Corp.

Who bought BioSpecifics Technologies Corp stock? Who is buying BioSpecifics Technologies Corp stock?

BioSpecifics Technologies Corp's stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Goldman Sachs Group Inc., Renaissance Technologies LLC, Rice Hall James & Associates LLC, Dimensional Fund Advisors LP, OxFORD Asset Management LLP, State Street Corp and AJO LP. View Insider Buying and Selling for BioSpecifics Technologies Corp.

How do I buy BioSpecifics Technologies Corp stock?

Shares of BioSpecifics Technologies Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies Corp's stock price today?

One share of BioSpecifics Technologies Corp stock can currently be purchased for approximately $46.16.


MarketBeat Community Rating for BioSpecifics Technologies Corp (NASDAQ BSTC)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioSpecifics Technologies Corp (NASDAQ:BSTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $72.00 (55.98% upside)

Analysts' Ratings History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017HC WainwrightSet Price TargetBuy$72.00HighView Rating Details
8/10/2016Rodman & RenshawReiterated RatingBuy$60.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Earnings by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Earnings History by Quarter for BioSpecifics Technologies Corp (NASDAQ BSTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017        
3/15/2017Q4 2016$0.38$0.40$6.76 million$6.62 millionViewN/AView Earnings Details
11/9/2016Q3 2016$0.41$0.42$6.95 million$6.88 millionViewListenView Earnings Details
8/9/2016Q216$0.35$0.35$6.25 million$6.20 millionViewN/AView Earnings Details
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details
11/10/2014Q314$0.19$0.20$4.00 million$4.00 millionViewN/AView Earnings Details
8/11/2014Q214$0.12$0.08$2.91 million$2.70 millionViewN/AView Earnings Details
5/8/2014Q114$0.07$0.11$2.46 million$2.80 millionViewN/AView Earnings Details
3/6/2014$0.17$0.25ViewN/AView Earnings Details
11/12/2013Q3$0.04$0.17ViewListenView Earnings Details
8/8/2013Q2 2013$0.02$0.15ViewN/AView Earnings Details
5/10/2013Q1 2013$0.18$0.19ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Current Year EPS Consensus Estimate: $1.59 EPS
Next Year EPS Consensus Estimate: $1.69 EPS

Dividends

Dividend History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Insider Ownership Percentage: 21.54%
Institutional Ownership Percentage: 55.95%
Insider Trades by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Insider Trades by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Thomas WegmanInsiderSell20,000$48.16$963,200.00View SEC Filing  
11/29/2016Toby WegmanDirectorSell10,000$48.08$480,800.00View SEC Filing  
9/15/2016Thomas WegmanInsiderSell3,100$41.21$127,751.00View SEC Filing  
9/13/2016Thomas WegmanInsiderSell3,605$37.55$135,367.75View SEC Filing  
9/2/2016Thomas WegmanInsiderSell9,201$37.53$345,313.53View SEC Filing  
8/30/2016Thomas WegmanInsiderSell4,299$37.54$161,384.46View SEC Filing  
8/24/2016Thomas WegmanPresidentSell4,173$38.08$158,907.84View SEC Filing  
8/23/2016Thomas WegmanPresidentSell4,100$38.60$158,260.00View SEC Filing  
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00View SEC Filing  
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00View SEC Filing  
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00View SEC Filing  
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92View SEC Filing  
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44View SEC Filing  
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.00View SEC Filing  
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.00View SEC Filing  
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Latest Headlines for BioSpecifics Technologies Corp (NASDAQ:BSTC)
Source:
DateHeadline
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 5:34 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : September 18, 2017
finance.yahoo.com - September 18 at 5:07 PM
finance.yahoo.com logoShould You Buy BioSpecifics Technologies Corp (BSTC) At This PE Ratio?
finance.yahoo.com - September 15 at 10:11 PM
seekingalpha.com logoBioSpecifics Tech (BSTC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 4:08 AM
finance.yahoo.com logoBiospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 5:58 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp (BSTC) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - August 25 at 8:54 AM
americanbankingnews.com logoBioSpecifics Technologies Corp (BSTC) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - August 19 at 12:56 PM
americanbankingnews.com logoBioSpecifics Technologies Corp (NASDAQ:BSTC) Cut to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - August 11 at 6:42 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 4:56 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp (BSTC) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - August 8 at 6:26 PM
finance.yahoo.com logoBiospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : August 4, 2017
finance.yahoo.com - August 3 at 11:19 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 21, 2017
finance.yahoo.com - July 21 at 6:21 PM
americanbankingnews.com logo BioSpecifics Technologies Corp (NASDAQ:BSTC) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - July 21 at 11:18 AM
americanbankingnews.com logoBioSpecifics Technologies Corp (BSTC) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 11 at 7:14 PM
finance.yahoo.com logoETFs with exposure to Biospecifics Technologies Corp. : July 11, 2017
finance.yahoo.com - July 11 at 5:47 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 10, 2017
finance.yahoo.com - July 10 at 3:15 PM
americanbankingnews.com logo BioSpecifics Technologies Corp (BSTC) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - June 22 at 12:38 PM
finance.yahoo.com logoETFs with exposure to Biospecifics Technologies Corp. : June 19, 2017
finance.yahoo.com - June 19 at 4:15 PM
americanbankingnews.com logoHead-To-Head Analysis: Amgen (AMGN) & BioSpecifics Technologies Corp (BSTC)
www.americanbankingnews.com - June 19 at 10:32 AM
finance.yahoo.com logoBiospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:47 PM
seekingalpha.com logoBioSpecifics Technologies (BSTC) Presents At Jefferies 2017 Global Healthcare Conference
seekingalpha.com - June 10 at 2:39 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 2 at 5:28 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp. (BSTC) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 1 at 12:46 PM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 23 at 9:48 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : May 18, 2017
finance.yahoo.com - May 18 at 11:30 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 15 at 5:42 PM
americanbankingnews.com logo Brokerages Set $72.00 Price Target for BioSpecifics Technologies Corp. (BSTC)
www.americanbankingnews.com - May 12 at 11:20 AM
reuters.com logoBRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46
www.reuters.com - May 11 at 4:38 PM
finance.yahoo.com logoBioSpecifics posts 1Q profit
finance.yahoo.com - May 10 at 11:55 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 4:15 PM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 1:01 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 12:41 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Earns News Sentiment Rating of 0.50
www.americanbankingnews.com - May 3 at 3:46 PM
americanbankingnews.com logoPositive News Coverage Somewhat Likely to Affect BioSpecifics Technologies Corp. (BSTC) Stock Price
www.americanbankingnews.com - April 28 at 9:34 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp. (BSTC) Given $72.00 Average Price Target by Analysts
www.americanbankingnews.com - April 26 at 9:59 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Receiving Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 25 at 3:54 PM
finance.yahoo.com logoBiospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : April 21, 2017
finance.yahoo.com - April 21 at 4:10 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : April 20, 2017
finance.yahoo.com - April 20 at 10:49 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
finance.yahoo.com - April 18 at 12:38 PM
americanbankingnews.com logoVery Positive News Coverage Somewhat Likely to Impact BioSpecifics Technologies Corp. (BSTC) Stock Price
www.americanbankingnews.com - April 18 at 9:28 AM
americanbankingnews.com logoFavorable Press Coverage Somewhat Likely to Effect BioSpecifics Technologies Corp. (BSTC) Share Price
www.americanbankingnews.com - April 13 at 4:17 PM
finance.yahoo.com logoETFs with exposure to Biospecifics Technologies Corp. : April 7, 2017
finance.yahoo.com - April 7 at 9:03 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : April 7, 2017
finance.yahoo.com - April 7 at 4:02 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp. (BSTC) Given $72.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - April 6 at 10:15 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 29 at 9:22 PM
americanbankingnews.com logoZacks Investment Research Upgrades BioSpecifics Technologies Corp. (BSTC) to "Buy"
www.americanbankingnews.com - March 27 at 8:35 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 21 at 5:00 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 10:44 PM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 10:43 AM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 15 at 9:25 PM

Social

Chart

BioSpecifics Technologies Corp (BSTC) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff